In Depth 13 Aug 2025 Injecting hope into skin cancer treatment: The promise of melanoma vaccines Discover how melanoma vaccines are gaining traction in the clinic and could soon become a treatment option for this deadly skin cancer. August 13, 2025 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 6 Sep 2024The power of tumor infiltrating lymphocytes to fight melanoma Listen to our conversation with Brian Gastman, EVP of medical affairs at Iovance Biotherapeutics, about TILs and the company’s pipeline. September 6, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
News and Trends 27 Aug 2024 Could microbiome drugs be the key to unlocking checkpoint inhibitors’ potential? As Microbiotica announces phase 1 approval for two microbiome drugs we delve into their potential in oncology and beyond. August 27, 2024 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2023 Cytovation melanoma study under way Cytovation ASA, a Norwegian clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane immunotherapy, announces that the first patient has been dosed in its phase 2a study. The trial is investigating CyPep-1 monotherapy in patients with advanced melanoma refractory to checkpoint inhibitors (CPIs). The study is an expansion arm […] February 16, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2022 Proscia presents results on AI melanoma diagnostic predictions Proscia has released study results on new artificial intelligence (AI) that predicts diagnostic agreement for melanoma, the deadliest form of skin cancer. The findings, presented at the European Conference on Computer Vision (ECCV) 2022, highlight the potential of the technology to improve diagnostic accuracy for melanoma and other diseases with low pathologist concordance. Conducted at […] November 1, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2022 OncoSec slashing staff numbers to prioritize pipeline OncoSec Medical Incorporated is restructuring to prioritize development of its lead clinical candidate TAVO (TAVO-EP). TAVO is a plasmid encoding interleukin 12 (IL-12) delivered by intratumoral electroporation. Oncosec is reducing its staff by approximately 45% and prioritizing clinical pipeline activities to reduce operating expenses. The company and remaining employees will focus clinical activities in melanoma […] October 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Sponsored by Biognosys 27 Sep 2022 Using the power of proteomics to predict immunotherapy responses in melanoma and beyond Next-generation proteomics has a vital role to play in the search for new biomarkers of immunotherapy response. Recent studies in melanoma presented at the European Society for Medical Oncology (ESMO) Congress highlight how these insights have the potential to transform cancer care. The recent success of immunotherapies that manipulate the patient’s immune system to recognize […] September 27, 2022 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2022 Swiss scientists reduce resistance of dormant melanoma cells Small-molecule targeted therapies revolutionized the treatment of metastatic melanoma, provided that the tumors carry the mutations to respond to these treatments. However, despite an initial response that can be seen in a majority of patients, most of them will undergo relapse even after sometimes spectacular initial responses. These relapses are due to “dormant” persistent cells, […] September 22, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Nov 2019 UK Biotech Launched to Target ‘Dark Antigens’ with Cancer Vaccines The London-based startup Ervaxx has launched with a €15.8M Series A round to develop cancer vaccines and cell therapies that target ‘dark antigens’ — normally silent genes in the genome that are expressed in cancer cells. Ervaxx’s Series A round was funded by the transatlantic venture capital firm SV Health Investors, as well as an […] November 6, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Sep 2019 UK Biotech’s Personalized Immunotherapy gets €110M Series B Boost The UK company Achilles Therapeutics has raised €110M (£100M) to test its personalized cancer cell immunotherapies in humans for the first time. The large Series B round will fund two phase I/IIa clinical trials of Achilles’ preclinical immunotherapy which are expected to start this year: one in non-small cell lung cancer and the other in […] September 3, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 5 Jul 2019 This Biotech Helps the Immune System to Infiltrate and Destroy Tumors The Nice-based biotech company Yukin Therapeutics is developing drugs that can work together with checkpoint inhibitors to help the immune system smash tumors such as melanoma. Mission: To develop a drug that can change the tumor microenvironment to allow the immune system to infiltrate and destroy the tumor more effectively. This could give a big […] July 5, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 24 Jul 2018 Meet the Dutch Scientists who Invented Keytruda, “The President’s Drug” Known for curing US President Jimmy Carter’s cancer, Keytruda continues to benefit many other cancer patients. The inventors told us their story, from the drug’s early days to their current role as executives of the biotech unicorn Aduro. Since 2014, the cancer drug Keytruda, also known as pembrolizumab, continues to be widely sought after due […] July 24, 2018 - 6 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email